Telomir Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Telomir Pharmaceuticals, Inc. (TELO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $198.73 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $198.73K, a 94.80% decline year-over-year.
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $39.80K, a 97.11% decline year-over-year.
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $98.14K, a 97.96% decline year-over-year.
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.82M.
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.29M, a 22.96% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.87M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $198.73K 10-Q · filed 2026-08-13 | $238.54K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $39.80K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $5.29M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $98.14K 10-Q · filed 2025-11-10 | $3.92M derived: sum of 2 quarters · filed 2026-08-13 | $5.30M derived: sum of 3 quarters · filed 2026-08-13 | $7.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.82M 10-Q · filed 2026-08-13 | $5.20M derived: sum of 2 quarters · filed 2026-08-13 | $7.26M derived: sum of 3 quarters · filed 2026-08-13 | $12.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.38M 10-Q · filed 2026-08-13 | $3.44M derived: sum of 2 quarters · filed 2026-08-13 | $8.24M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2024-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.87M derived: sum of 2 quarters · filed 2026-03-17 | $6.87M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $4.81M 10-Q · filed 2025-11-10 | $4.81M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |